461
Participants
Start Date
October 30, 2020
Primary Completion Date
February 13, 2023
Study Completion Date
January 31, 2026
Atezolizumab
Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Tiragolumab
Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
Paclitaxel
Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
Cisplatin
Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
Atezolizumab Matching Placebo
Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Tiragolumab Matching Placebo
Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
National Taiwan University Hospital, Zhongzheng Dist.
Chulalongkorn Hospital, Bangkok
Rajavithi Hospital, Bangkok
Ramathibodi Hospital, Bangkok
National Cancer Center, Goyang-si
Siriraj Hospital, Bangkok
Anhui Province Cancer Hospital, Hefei
Seoul National University Bundang Hospital, Seongnam-si
Kyungpook National University Chilgok Hospital, Daegu
Songklanagarind Hospital, Songkhla
Beijing Cancer Hospital, Beijing
Liaoning Provincial Cancer Hospital, Shengyang
Taipei Veterans General Hospital, Taipei
the First Hospital of Jilin University, Changchun
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Chest Hospital, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Jiangsu Province Hospital of Chinese Medicine, Nanjing
Jiangsu Cancer Hospital, Nanjing
Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ), Wuxi
The First People's Hospital of Lian Yun Gang, Lianyungang
Northern Jangsu People's Hospital, Yangzhou
Nan Tong Tumor Hospital, Nantong
Anhui Provincial Hospital, Anhui
The Second Affiliated Hospital of Anhui Medical University, Hefei
Linyishi Cancer Hospital, Linyi
Tianjin Cancer Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Zhongshan Hospital Xiamen University, Xiamen
Chongqing Sanxia Central Hospital, Chongqing
Hunan Cancer Hospital, Changsha
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hubei Cancer Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Anyang Tumor Hosptial, Anyang
The First People's Hospital of Foshan, Foshan
Southern Medical University Nanfang Hospital, Guangdong Province Guangzhou City
Cancer Hospital of Shantou University Medical College, Shantou
Sichuan Provincial Cancer Hospital, Chengdu
West China Hospital, Sichuan University, Chengdu
Suining Central Hospital, Suining
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital), Xi'an
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an
Gansu Province People Hospital, Lanzhou
Beijing Luhe Hospital Capital Medical University, Beijing
Fujian Provincial Hospital, Fuzhou
Huai'an First People's Hospital, Huai'an
The Second People's Hospital of Huai'an, Huai'an
Affiliated Hopsital of Jining Medical University, Jining
Weifang People's Hospital, Weifang
Xiangyang Central Hospital, Xiangyang
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang
Xuzhou Central Hospital, Xuzhou
Queen Mary Hospital, Hong Kong
Prince of Wales Hosp, Shatin
Chang Gung Medical Foundation - Kaohsiung, Kaohisung
Affiliated Hospital of Chengde Medical University, Chengde
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Korea University Guro Hospital, Seoul
National Cheng Kung University Hospital, Tainan City
Hoffmann-La Roche
INDUSTRY